Orakl Oncology

Bringing better cancer treatments to patients faster
Website
The problem

Around 95% of oncology drugs fail during clinical development. Every tumour is different, and predicting which treatments will actually work in patients remains one of the industry's biggest challenges.

Location

France

The solution

Orakl combines AI with real patient biology, growing patient-derived tumour cells in the lab to test how they respond to treatments. Its AI has demonstrated 90% accuracy in predicting cancer clinical trial outcomes, helping pharma identify the most promising drugs years before they reach the clinic.

Investment year

2026

Bringing better cancer treatments to patients faster
Website
Sector

Healthtech

Investment stage

Series A

Bringing better cancer treatments to patients faster
Website
Sector
Healthtech
Location
France
Investment stage
Series A
Investment year
2026
The problem

Around 95% of oncology drugs fail during clinical development. Every tumour is different, and predicting which treatments will actually work in patients remains one of the industry's biggest challenges.

The solution

Orakl combines AI with real patient biology, growing patient-derived tumour cells in the lab to test how they respond to treatments. Its AI has demonstrated 90% accuracy in predicting cancer clinical trial outcomes, helping pharma identify the most promising drugs years before they reach the clinic.

Similar Companies